[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hopital Foch\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":411},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,53,77,99,121,147,170,196,218,240,266,286,316,337,360,386],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100641783","interaction-between-decidual-cells-and-nk-cells-in-endometriosis-100641783",false,"NCT07652593","Interaction Between Decidual Cells and NK Cells in Endometriosis","Interaction Between Decidual Cells and Natural Killer Cells in Endometriosis: A Prospective Pilot Case-Control Study","PAINLESS","Inclusion Criteria:\n\n* Endometriosis Group\n* Female participant aged 18 years or older.\n* Confirmed diagnosis of deep endometriosis by imaging or surgery.\n* Pelvic pain and\u002For severe dysmenorrhea (Visual Analog Scale \\> 4).\n* Premenopausal.\n* No contraceptive or hormonal treatment during the study menstrual cycle.\n* Affiliated with a health insurance system.\n* Able and willing to provide written informed consent.\n* Control Group\n* Female participant aged 18 years or older.\n* No diagnosis of endometriosis.\n* Premenopausal.\n* No contraceptive or hormonal treatment during the study menstrual cycle.\n* No chronic pelvic pain or severe dysmenorrhea (Visual Analog Scale \\\u003C 4).\n* Affiliated with a health insurance system.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Current infection.\n* Active cancer.\n* Active autoimmune disease.\n* Concomitant hormonal treatment.\n* Pregnancy.\n* Participant under guardianship or legal protection.\n* Participant deprived of liberty.","FEMALE","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","Endometriosis is a chronic gynecological disease characterized by the presence of endometrial-like tissue outside the uterus and is frequently associated with pelvic pain and infertility. Increasing evidence suggests that immune dysfunction may contribute to the development and persistence of the disease.\n\nThe purpose of this prospective case-control study is to compare immune cell characteristics in women with deep endometriosis and women without endometriosis during the secretory phase of the menstrual cycle. Participants will undergo collection of clinical data, blood samples, endometrial samples, and vaginal microbiota samples. For participants undergoing clinically indicated pelvic surgery, additional biological samples may be collected during the procedure. The study aims to improve understanding of the immune mechanisms involved in endometriosis and to identify potential biomarkers associated with the disease.",[27],"Endometriosis",[27,29,30,31,32,33,34,35,36,37,38,39],"Deep Endometriosis","Natural Killer Cells","NK Cells","Endometrial Immune Microenvironment","CD39","Immunology","Vaginal Microbiota","Pelvic Pain","Cytokines","Women's Health","Biomarkers","NOT_YET_RECRUITING","2026-06-11",{"date":43,"type":44},"2026-06-17","ACTUAL",{"date":46,"type":21},"2026-06",{"date":48,"type":21},"2027-10",{"name":50,"class":51},"Hopital Foch","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":52},"100557078","clinical-and-economic-comparison-of-2-methods-of-intubation-tube-fixation--anchorfasttm-versus-current-cord-fixation-100557078","NCT06533436","Clinical and Economic Comparison of 2 Methods of Intubation Tube Fixation : AnchorFastTM Versus Current Cord Fixation","Clinical and Economic Comparison of 2 Methods of Intubation Tube Fixation in the Intensive Care Unit: Benefits of Intubation Tube Fixation With AnchorFastTM Versus Current Cord Fixation","AnchorDon","Inclusion Criteria:\n\n* Patient over 18 years old,\n* Patient with orotracheal intubation,\n* Patient intubated no more than 24 hours previously,\n* Oral consent from patient, trusted support person or relative if unable to consent\n* Membership of a French health insurance scheme.\n\nExclusion Criteria:\n\n* Pre-existing facial, labial or auricular skin lesions,\n* Pre-existing mucositis,\n* Patients extubated for more than 24 hours whose condition requires a new intubation tube\n* Nasotracheal intubation,\n* Planned early tracheotomy,\n* Patient with occipital craniectomy,\n* Patient in ventral position,\n* Pregnant or breast-feeding woman,\n* Patient deprived of liberty or under guardianship.","ALL",{"count":63,"type":21},350,[24],"The aim of this study is to assess the benefits of using the Anchorfast device in reducing complications associated with intubation tube fixation, in terms of the rate of pressure ulcer development, the rate of intubation tube mobilization and the rate of VAP occurrence. If the hypothesis is confirmed, this project would enable the caregivers to optimize the current practice in the interests of both patients and caregivers. That's why the investigators have designed a real-life study, and will also be looking at the effect of care load on and caregiver satisfaction.",[67,68],"Intubation Complication","Eschar","RECRUITING","2026-06-09",{"date":41,"type":44},{"date":73,"type":44},"2024-08-02",{"date":75,"type":21},"2027-03-01",{"name":50,"class":51},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100400620","assessment-of-the-efficacy-and-safety-of-eess-in-patients-with-incomplete-spinal-cord-injuries-100400620","NCT04496609","Assessment of the Efficacy and Safety of EESS in Patients With Incomplete Spinal Cord Injuries","Assessment of the Efficacy and Safety of Epidural Electrical Stimulation of the Lumbosacral Spinal Cord in the Symptomatic Treatment of Motor, Vesico-sphincter and Genito-sexual Disorders in Patients With Incomplete Spinal Cord Injuries","Parastim","Inclusion Criteria:\n\n* Aged between 18 and 65 years inclusive\n* Male or female\n* Incomplete ASIA B or C spinal cord lesion with level of lesion located above T10 (sensation preserved below level of lesion)\n* Absence of significant motor deficit of the upper limbs or recovered motor deficit (muscular score ≥ 4\u002F5)\n* Patient with spinal cord injury at least 2 years old and considered stable not walking\n* Spinal cord lesion determined by spinal cord MRI (intramedullary hypersignal)\n* Patient who can benefit from an iterative rehabilitation programme\n* Patient with stable health condition with no cardiopulmonary disease\n* Patient with orthopaedic condition compatible with verticality and walking\n* Persistence of adductor reflexes up to L2\n* Patient with no current neuromodulation implant: spinal cord neurostimulator, brain, peripheral nerve or intrathecal treatment\n* Patient with no coagulopathy, cardiac risk factors or other medical risk factors significant for surgery\n* Local anatomical conditions compatible with implantation of the epidural electrode (determined by MRI of the spinal cord)\n* Person who benefits from or is entitled to a social security scheme\n* Having provided signed informed consent\n\nExclusion Criteria:\n\n* Significant cerebral lesion on a previous cerebral MRI\n* Psychiatric or cognitive disorder history (known or detected during the consultation with the psychologist)\n* Protected adult patients\n* Pregnant (determined by a negative pregnancy test) or breastfeeding women\n* Respiratory failure (vital capacity \\\u003C 50%) (surgery in prone position)\n* Repeated urinary infections (≥3 per year)\n* Planned absence that may hinder participation in the study (travelling abroad, relocation, imminent moving)\n* Patients with spasms (PENN scale \\> 2)\n* Cauda equina syndrome\n* Patients presenting with a contraindication to an MRI being carried out: i) pacemaker, ii) non-MRI-compatible heart valve, iii) clips, stents, coils, etc. that are not MRI-compatible, iv) cochlear implant, v) metal foreign body, etc.)\n* Patients presenting with a contraindication to MEPs being carried out (notably wearing of ferromagnetic material, heart stimulator)\n* Patients on oral anticoagulants\n* Patients with botulinic toxin injection\n* Patients with bedsore\n* Undernourished patients (BMI \\\u003C 19)","65 Years",{"count":87,"type":21},14,[24],"Neurological disability caused by traumatic lesions of the spinal cord is a significant challenge for medicine and society. These lesions, leading to sublesional central nervous system dysfunction, include sensorimotor, vesico-sphincter and genito-sexual disorders. To date, there is no treatment that enables spinal cord function to be restored.\n\nPreclinical studies have been able to demonstrate the recovery of locomotor activity with a combination of locomotor training, pharmacological intervention and epidural electrical stimulation of the lumbosacral spinal cord (EESS) in adult rats with spinal cord transection. An American team have recently been able to show that EESS, combined with locomotor training, caused neurological improvement in four paraplegic patients, with electromyographic muscular activation patterns similar to those observed during walking. In fact, these authors also showed an improvement, under stimulation, of the VS and GS functions, but with no detailed documentation.\n\nStarting with a conceptual and preclinical rationale, and with proof of clinical concept demonstrated in several reported cases, we propose a clinical trial with an original cross-over design to validate the hypothesis that EESS combined with training in patients with incomplete spinal cord injuries would, with a good tolerance profile, allow motor, vesico-sphincter (VS) and genito-sexual (GS) disorders to be restored in patients with incomplete spinal cord injuries.",[91],"Spinal Cord Injuries",{"date":41,"type":44},{"date":94,"type":44},"2021-07-12",{"date":96,"type":21},"2029-07-12",{"name":50,"class":51},2,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100637320","cristel-study-monitoring-of-pregnancies-in-women-after-solid-organ-transplantation-100637320","NCT07592806","CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation","CRISTEL","Inclusion Criteria:\n\n* Female patient aged 18 years or older and of childbearing age\n* Has received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney)\n* Has a positive blood beta-hCG test result \\> 5 IU\u002FL (\"positive\")\n* Has signed an informed consent form\n* Affiliated with a health insurance plan\n\nExclusion Criteria:\n\n* Patient deprived of liberty or under legal guardianship\n* Patient refuses to participate in the study","48 Years",{"count":108,"type":21},2000,[24],"The objective of this research is to obtain standardized and independent data on the number of pregnancies occurring in France and their follow-up up to 1 year postpartum (or post-pregnancy termination). This study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will enable the dissemination of clear and up-to-date information to the medical community, thus contributing to better patient counseling and, more broadly, to couples. They will also serve to issue recommendations to optimize the planning and follow-up of pregnancies in women with solid organ transplants. Finally, this initiative aims to promote clinical research on pregnancies.",[112],"Surgical Operation With Transplant of Whole Organ","2026-05-11",{"date":115,"type":44},"2026-05-18",{"date":117,"type":21},"2026-09-01",{"date":119,"type":21},"2036-09-01",{"name":50,"class":51},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":52},"100389882","phase-2-benefit-of-gnrh-agonist-before-frozen-embryo-transfer-in-patients-with-endometriosis-andor-adenomyosis-100389882","NCT04356664","Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and\u002For Adenomyosis","Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and \u002F or Adenomyosis: Randomized Prospective Study","DECATEC","Inclusion Criteria:\n\n* Women aged 18 to 36 years (women ≥18 years to \\\u003C36 years) with endometriosis and \u002F or adenomyosis\n* Having benefited from In vitro fertilisation \u002Fintracytoplasmic micro-injection with freeze all and for whom the frozen embryon transfer of a blastocyst is planned\n* A normal uterine cavity\n* An MRI showing endometriosis and \u002F or adenomyosis during the inclusion visit\n* Having signed a consent form\n* Being affiliated to a Health Insurance Plan.\n\nExclusion Criteria:\n\n* Patient aged \\\u003C18 years and ≥ 36 years\n* BMI\\> 35\n* History of implantation failures (≥ 2)\n* Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra\n* known hydrosalpinx uni or bilateral\n* MRI showing no endometriosis or adenomyosis\n* Hypersensitivity to GnRH, GnRH analogues, or any of the excipients of Decapeptyl 3 mg\n* Known hypersensitivity to estradiol\n* Known hypersensitivity to progesterone\n* Known hypersensitivity to acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs\n* Known hypersensitivity to folic acid\n* Known hypersensitivity to cefixime or an antibiotic in the cephalosporin group\n* Known hypersensitivity to levofloxacin or any other quinolone\n* History of tendinopathies related to the administration of fluoroquinolones\n* Epilepsy\n* Hypersensitivity to contrast agents for MRI\n* Known or suspected breast cancer or history of breast cancer\n* Known or suspected genital tract cancer or history of genital cancer\n* known or suspected estrogen-dependent malignant neoplasms\n* Undiagnosed genital haemorrhage\n* Untreated endometrial hyperplasia\n* History of idiopathic venous thrombo-embolic accident or evolving venous thrombo-embolic event (deep vein thrombosis, pulmonary embolism)\n* Recent or evolving arterial thromboembolic stroke (eg angina, myocardial infarction)\n* Acute liver disease or history of liver disease, until hepatic tests are normalized\n* Severe renal insufficiency\n* Severe, uncontrolled heart failure\n* Evolutionary gastroduodenal ulcer\n* History of asthma caused by the administration of salicylates or substances of similar activity, especially nonsteroidal anti-inflammatory drugs\n* GnRH Agonist Decapeptyl administered within 6 months prior to transfer\n* To be deprived of liberty or under guardianship\n* Pregnancy and breast feeding.","36 Years",{"count":131,"type":21},180,[133,134],"PHASE2","PHASE3","Women suffering from endometriosis and\u002For adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.",[27,137,138],"Adenomyosis","Infertility, Female","2026-01-15",{"date":141,"type":44},"2026-01-16",{"date":143,"type":44},"2021-03-18",{"date":145,"type":21},"2026-06-18",{"name":50,"class":51},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":52},"100557426","interest-of-late-images-for-the-assessment-of-extensions-in-18fgd-pet-ct-of-muscle-invasive-bladder-cancers-100557426","NCT06537960","Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers","Intérêt Des Images Tardives Pour le Bilan d'Extensions en TEP-TDM au 18FGD Des Cancers de Vessie Infiltrant le Muscle (TARDITEP)","TARDITEP","Inclusion Criteria:\n\n* Patient 18 years of age or older,\n* With histologically proven muscle-invasive bladder cancer (≥pT2) at endoscopic bladder resection,\n* Scheduled to undergo 18FDG PET-CT in the nuclear medicine department at Hôpital Foch,\n* Having signed a consent form,\n* Affiliated to a health insurance scheme.\n\nExclusion Criteria:\n\n* Patient with a history of pelvic or genitourinary cancer,\n* Patient with known metastatic disease,\n* Patient with a contraindication to 18FDG PET-CT,\n* Pregnant or breast-feeding woman,\n* Patient deprived of liberty or under guardianship.",{"count":156,"type":21},66,[24],"The goal of this study is to demonstrate a significant gain in sensitivity versus surgical curage (extended pelvic) for initial lymph node staging of late FDG-PET images (2.5 hours) versus standard images (1 hour), analyzed by side (right iliac\u002Fleft iliac areas in Patients with muscle-invasive bladder tumor (MIBT) (≥pT2) referred for FDG-PET in the nuclear medicine department of Hôpital Foch as part of their initial extension workup.\n\nBefore performing 18FDG PET-CT, the operator checks that the patient has fasted for at least 6 hours and that blood glucose levels are below 11 mmol\u002Fl. In the absence of contraindication, intravenous (IV) injection of the radiopharmaceutical (18FDG at a dose of 3 MBq\u002Fkg) and a diuretic (Furosemide 20mg) will be performed as part of routine care. The 18FDG PET-CT scan will be performed in 2 phases:\n\n1st phase: Standard acquisition (vertex to mid-thigh) at 1 hour post-injection of radiotracer. PET acquisition is coupled to a \"base-dose\" CT scan in spontaneous contrast, for anatomical location, measurement of lymph node size, and creation of an attenuation map, necessary for correction of attenuation and diffusion on PET images (DLP estimated at around 500 mGy.cm on average). Micturition is performed as part of routine care just before the first acquisition.\n\nPhase 2: Complementary abdomino-pelvic acquisition at 2.5 hours post-injection (2 or 3 steps depending on patient size. This second PET acquisition is coupled to an \"ultra-base-dose\" CT scan in spontaneous contrast, to be used only for attenuation and diffusion correction (DLP estimated at around 100 mGy.cm on average). Micturition is performed 30 minutes before the second acquisition.\n\nThe patient's proposed therapeutic management will be decided at the PCR once the extension work-up has been carried out, as part of routine care. For this purpose, only \"standard\" 18FDG PET-CT images may be used.\n\nAs a general rule, patients with distant metastases (stage pT2N+M+) will receive palliative treatment, while surgical treatment from the outset, or after chemotherapy for patients with stage pT2N0M0 or pT2N+M0, will be discussed on a case-by-case basis at the multidisciplinary consultation meeting.\n\nLate\" images will be used after lymph node curage, in patients who have not had chemotherapy prior to surgery (cystectomy + extended pelvic lymph node curage), to determine the sensitivity of these complementary images.",[160,161],"Muscle-Invasive Bladder Carcinoma","Bladder Cancer","2025-11-18",{"date":164,"type":44},"2025-11-21",{"date":166,"type":44},"2023-12-14",{"date":168,"type":21},"2027-03-15",{"name":50,"class":51},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100435049","phase-2-oxidative-phosphorylation-targeting-in-malignant-glioma-using-metformin-plus-radiotherapy-temozolomide-100435049","NCT04945148","Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide","OPTIMUM","Inclusion Criteria:\n\n1. Provision of signed informed consent for selection and treatment phase obtained from the patient\u002Flegal representative prior to performing any protocol-related procedures,\n2. Patients must be willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits, and examinations including follow-up,\n3. Newly-diagnosed histologically-confirmed supra-tentorial IDHwt glioblastoma (Grade 4 malignant glioma by World Health Organization, including gliosarcoma),\n4. OXPHOS+ subtype by the central laboratory\n5. No prior treatment for GBM other than surgery,\n6. Substantial recovery from surgical resection, no major ongoing safety issues (eg, infection requiring I.V. antibiotics) following surgery,\n7. Without corticosteroids or with stable dose of corticosteroids (ie ≤ dexamethasone 6 mg, methylprednisolone 30 mg or prednisone 38 mg),\n8. ECOG (Eastern Cooperative Oncology Group) performance status 0-2,\n9. Able to receive concomitant radio-chemotherapy according to the Stupp protocol (60Gy) based on investigator judgment,\n10. Adequate bone marrow and normal hepatic function,\n11. Creatinine clearance ≥ 30 mL\u002Fmin (between 30 and 50 ml\u002Fmin, patients will be prescribed no more than 1500mg of metformin),\n12. Able to start RT within 7 weeks after histological diagnosis,\n13. Patients must have life expectancy ≥ 16 weeks,\n14. Patients affiliated to an appropriate health insurance system,\n15. Age ≥ 18 years old,\n16. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of HCG) within 7 days prior to the start of study drug,\n17. Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception from the signing of the informed consent and continue throughout period of taking study treatment and for 30 days after last dose of study drug (duration of ovulatory cycle) plus the time required for the investigational drug to undergo five half-lives (both TMZ and metformin). The terminal half-life of temozolomide is 1.8 hours. The terminal half-life for metformin is 6.5 hours.\n18. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception throughout the period of taking study treatment and for 6 months plus the time required for the investigational drug to undergo five half-lives (both TMZ and metformin). The terminal half-life of temozolomide is 1.8 hours. The terminal half-life for metformin is 6.5 hours.\n19. White blood cells (WBC) ≥ 2000\u002FμL\n20. Neutrophils ≥ 1500\u002FμL,\n21. Platelets ≥ 100 x103\u002FμL,\n22. Hemoglobin ≥ 9.0 g\u002FdL,\n23. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 30 mL\u002Fmin (using the Cockcroft-Gault formula) Female CrCl = (140-age in years) x weight in kg x 0.85 72 x serum creatinine in mg\u002FdL Male CrCl = (140-age in years) x weight in kg x 1.00 72 x serum creatinine in mg\u002FdL\n24. Aspartate AminoTransferase (AST) ≤ 3.0 x ULN,\n25. Alanine Aminotransferase (ALT) ≤ 3.0 x ULN,\n26. Total Bilirubin ≤ 1.5 x ULN (except patients with Gilbert Syndrome who may have a total bilirubin \\\u003C 3.0 x ULN).\n\nExclusion Criteria:\n\n1. Prior treatment for GBM (other than surgical resection) including Gliadel wafer,\n2. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years,\n3. Any known metastatic extracranial or leptomeningeal disease,\n4. IDH mutant,\n5. Secondary GBM (ie, progression from prior low-grade or anaplastic glioma),\n6. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the patient to receive protocol therapy, or interfere with the interpretation of study results,\n7. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication (inflammatory bowel disease, major bowel resection),\n8. Pregnant or breast-feeding women,\n9. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving anti-viral therapy,\n10. Patients with known active hepatitis (i.e., Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV)),\n11. Patients with a known hypersensitivity to metformin and temozolomide or any of the excipients of the products,\n12. Patients with severe renal insufficiency ie, CrCl \\\u003C 30 mL\u002Fmin (who should not receive contrast materials),\n13. History or evidence upon physical\u002Fneurological examination of other central nervous system condition (eg, seizures, abscess) unrelated to cancer, unless adequately controlled by medication or considered not potentially interfering with protocol treatment,\n14. Patients unable (eg, due to pacemaker or Implantable Cardioverter Defibrillator (ICD) device) or unwilling to have a contrast-enhanced MRI of the head,\n15. Any acute medical condition that may impair renal function such as dehydration, severe infection, shock,\n16. Any disease which may cause tissue hypoxia such as decompensated heart failure, respiratory failure, recent myocardial infarction\n17. Past Diabetic precoma\n18. Past Acute metabolic acidosis,\n19. Alcohol intoxication and Alcoholism,\n20. Persons protected by a legal regime (guardianship, trusteeship),\n21. Prisoners or patients who are involuntarily incarcerated,\n22. Patients who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.",{"count":178,"type":21},640,[133],"Tailored approaches targeting crucial oncogenes and pathways have shown successful results in a number of cancer types and offer exciting perspective in neuro-oncology. IDH (Isocitrate dehydrogenase) wild-type (IDHwt) glioblastoma (GBM) (10%) present a unique and homogenous energetic metabolism which is specifically dependent on the oxidative phosphorylation (OXPHOS) rather than on the aerobic glycolysis. OXPHOS+ IDHwt GBMs overexpress mitochondrial markers and can be specifically inhibited by mitochondrial inhibitors in vitro and in vivo.\n\nMetformin is an oral inhibitor of mitochondrial complex I and is a widely used drug in diabetic and non-diabetic patients, safe and well tolerated in association with radiotherapy and chemotherapy.\n\nBasing on drastic effect, the investigators have observed in vivo (reduction of \\>50% of tumor growth) and hypothesize that metformin could be specifically efficient to treat up-front patients affected by OXPHOS+ GBM, in association with the standard first-line treatment with radiotherapy and temozolomide (RT-TMZ).\n\nThe investigators set up a dedicated molecular analysis including RNA assay and expression of OXPHOS markers for formalin-fixed paraffin-embedded tumors (FFPE), which allows to detect OXPHOS+ GBM at diagnosis.\n\nHere a phase II, open label, non-randomized multicenter trial including five French neurooncology centers (H. Foch-Suresnes, Pitié-Salpêtrière-Paris, Saint Louis-Paris, Lyon, Marseille) and one in Italy (Istituto Besta, Milan) is proposed.\n\nNewly diagnosed IDH wild-type GBM patients with the OXPHOS+ signature will be eligible for inclusion in this trial. The investigators expect to screen 640 patients and to include 64 patients over a period of 24 months with 24 months of follow-up.",[182],"Glioblastoma, IDH-wildtype",[184,185,186,187,188],"Glioblastoma","FGFR3-TACC3","Metformin","Radio-chemotherapy","OXPHOS+",{"date":164,"type":44},{"date":191,"type":44},"2024-05-10",{"date":193,"type":21},"2028-05",{"name":50,"class":51},7,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":52},"100376130","treatment-of-chronic-pelvic-pain-due-to-endometriosis-by-transcutaneous-auricular-vagus-nerve-stimulation-100376130","NCT04177511","Treatment of Chronic Pelvic Pain Due to Endometriosis by Transcutaneous Auricular Vagus Nerve Stimulation","Stim-Endom","Inclusion Criteria:\n\n* Women aged \\>= 15 years\n* With chronic pelvic pain and\u002F or dysmenorrhoea and\u002F or dyspareunia\n* Who has been cared for by a gynecologist in one of the institutions participating in the study\n* Diagnosed with endometriosis\n* Having signed an informed written consent\n* Affiliated to a health insurance scheme\n\nExclusion Criteria:\n\n* contraindication to the use of transcutaneous auricular vagus nerve stimulation (cardiac pathology, asthmatic patient)\n* pregnant or breastfeeding women\n* patient undergoing in vitro fertilization\n* associated pathology requiring long-term analgesic treatment\n* patient with atria trans vagal neurostimulation in the 12 months prior to inclusion\n* patient deprived of liberty or under guardianship","15 Years",{"count":205,"type":21},72,[24],"6-10% of women of childbearing age suffer from endometriosis, which is mainly manifested by dysmenorrhea, non-menstrual pelvic pain and dyspareunia. Several treatment strategies, including surgical ones, are proposed but they are sometimes insufficient because endometriosis-related pain is frequently accompanied by sensitization. Endometriosis surgery, when indicated, is therefore changeably effective, even though the lesions have been completely resected. Patients therefore consult Pain Units seeking for the effective treatment as the pain persist even after surgical management of endometriosis.\n\nVagus nerve stimulation is a non-invasive technique that includes an anti-inflammatory effect and a modulation of neurotransmitter production (adrenaline, norepinephrine; serotonin, acetylcholine). Yuan and Silberstein published a general review on the technique. Migraine and depression are one of the selected indications. In addition, Napadow et al. published favourable results in a short series of patients with chronic pelvic pain. The Investigators of this study have treated some patients with this technique with a result deemed satisfactory which leads to propose a randomized study to confirm this impression.",[27],[210,211],"Chronic pelvic pain","Transcutaneous Auricular Vagus Nerve Stimulation",{"date":164,"type":44},{"date":214,"type":44},"2021-12-13",{"date":216,"type":21},"2027-03-28",{"name":50,"class":51},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":52},"100409725","immunological-mechanisms-of-rejection-in-uterine-transplantation-100409725","NCT04615221","Immunological Mechanisms of Rejection in Uterine Transplantation","MARNI","Inclusion Criteria:\n\n* Patient going to or having received a uterine transplant OR Patient going to or having donated a uterus for a recipient included in the study OR Premenopausal woman to undergo gynecological surgery under general anesthesia: for 4 of them it was a hysterectomy and they must be under 45 years old, the other 6 must be under 38 years old.\n\nExclusion Criteria (For witness):\n\n* Pregnancy in progress\n* Current infection\n* Cervical dysplasia\n* History of transplant or transfusion\n* Cancer or history of cancer\n* Menopause\n* Patient aged 38 or over for the 6 controls without hysterectomy, patient aged 45 or over for the 4 patients with hysterectomy.\n* Endometriosis","45 Years",{"count":227,"type":21},30,[24],"The objective of this study is to understand the mechanisms of rejection in uterine transplantation and to search for non-invasive markers of rejection. The biological samples necessary for our research have been or will be collected during procedures (biopsies, smears, vaginal swab, blood tests) carried out as part of the scheduled follow-up of patients. These will be samples whose collection is minimally or not invasive",[231],"Transplant Rejection","2025-09-08",{"date":234,"type":44},"2025-09-12",{"date":236,"type":44},"2020-09-21",{"date":238,"type":21},"2033-09",{"name":50,"class":51},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":52},"100591470","interpretation-of-the-role-of-eosinophils-in-diffuse-interstitial-pneumopathies-100591470","NCT06980844","Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies","INTREPID","Inclusion Criteria:\n\n* PID-PNE interest group (n= 30 patients): Adult subjects followed for chronic interstitial lung disease with a follow-up duration \\> 1 year with at least one biological sample showing a circulating PNE level \\> 300\u002Fmm3 during their follow-up, without any prescription of systemic corticosteroid therapy and antifibrotic agents (PIRFENIDONE and NINTENADIB) responsible for modulation of the eosinophil count.\n\n  15 patients followed for Idiopathic Pulmonary Fibrosis (IPF) and 15 patients with another etiology of ILD will be selected.\n* PNE ILD control group (n= 30 patients): Adult subjects with ILD with a PNE level \\\u003C 150\u002Fmm3 during their follow-up, without any prescription of systemic corticosteroid therapy and antifibrotic agents (PIRFENIDONE and NINTENADIB). - Have signed a consent form.\n* Be affiliated with a health insurance plan.\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients over 75 years of age\n* Pregnant patients\n* Subjects with eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\n* Subjects with hypereosinophilic syndrome (NEP \\> 1500\u002Fmm3)\n* Subjects with chronic idiopathic eosinophilic pneumonia (Carrington disease)\n* Subjects with drug-induced interstitial lung disease\n* Subjects with respiratory failure (acute and chronic: SaO2 \\> 92% throughout the procedure)\n* Subjects with unstable heart disease\n* Subjects with severe comorbidities\n* Subjects receiving oxygen therapy\n* Subjects deprived of liberty or under guardianship -Patients subject to a guardianship and judicial safeguard measure\n* PID-PNE or non-PID PNE patients receiving systemic corticosteroid therapy or antifibrotic treatment (PIRFENIDONE and NINTENADIB)","75 Years",{"count":249,"type":21},60,[24],"Diffuse interstitial lung diseases (ILDs) represent a group of rare, heterogeneous disorders of various etiologies, all sharing a common histopathological feature: fibrotic remodeling of the pulmonary parenchyma induced by a chronic inflammatory process. Although the prevalence of ILDs in France has recently been estimated at 19.4 per 100,000 inhabitants per year, they are frequently encountered in clinical practice due to their need for specialized hospital care. ILDs are associated with significant morbidity and a poor prognosis, despite the heavy burden of current therapeutic strategies. This highlights the urgent need to identify new therapeutic targets for these diseases.\n\nEosinophilic polymorphonuclear cell could represent one such target. As a source of pro-fibrotic mediators such as TGF-β, they may contribute to pulmonary fibrosis from a clinical standpoint. Our hypothesis is that a component of bronchial exacerbation in ILD patients may involve a type 2 immune response through the recruitment and activation of eosinophilic polymorphonuclear cell.\n\nGiven their role in pro-fibrotic signaling, our objective is to characterize type 2 immunity parameters-focusing in particular on eosinophilic polymorphonuclear cell-using a multi-source approach in a cohort of ILD patients. If type 2 immunity is significantly present in this population (referred to as ILD-eosinophilic polymorphonuclear cell), the investigators will investigate the role of eosinophilic polymorphonuclear cell in vitro using a co-culture model involving eosinophilic polymorphonuclear cell and respiratory epithelial cells (both bronchial and alveolar). Based on the results obtained, future prospects include evaluating the effects of biotherapy within this model as a preliminary step toward a subsequent clinical study.",[253],"Interstitial Lung Disease",[255,256,257],"T2 response","Eosinophil","Pulmonary fibrosis","2025-05-12",{"date":260,"type":44},"2025-05-20",{"date":262,"type":21},"2025-05-31",{"date":264,"type":21},"2029-02-28",{"name":50,"class":51},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":98},"100538746","phase-3-ursodeoxycholic-acid-udca-as-a-neuroprotective-adjuvant-treatment-to-rhegmatogenous-retinal-detachment-surgery-100538746","NCT06294847","Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery","UDCA","Inclusion Criteria:\n\n1. Aged 18 years or older,\n2. Scheduled to undergo surgical intervention through vitrectomy,\n3. Aphakic or pseudophakic patients,\n4. Experiencing rhegmatogenous retinal detachment affecting 2 quadrants or more,\n5. Presenting with macula OFF (raised macula) for 7 days or less before the onset of symptoms,\n6. Has signed a consent form,\n7. Affiliated with a health insurance plan.\n\nExclusion Criteria:\n\n1. Patients who have previously undergone vitrectomy for retinal detachment,\n2. Patients with vitreous hemorrhage or any other associated retinal pathologies,\n3. Monophthalmic patients,\n4. Women of childbearing age without effective contraceptive methods,\n5. Pregnant or lactating women,\n6. Hypersensitivity to the active substance, bile acids, or any of the excipients in Ursolvan® (see §6.1.1 of this protocol),\n7. Patients with peptic ulcers, acute or chronic liver disease, acute infection or inflammation of the gallbladder or bile ducts, recurrent gallstones, or obstruction of the bile ducts (common bile duct or cystic duct obstruction),\n8. Patients with radiopaque calcified gallstones,\n9. Patients with severe pancreatic disorders,\n10. Patients with Crohn's disease, ulcerative colitis, or other intestinal diseases that may alter the enterohepatic circulation of bile acids,\n11. Patients on oral treatment with cholestyramine, colestipol, antacids containing aluminum or magnesium hydroxide and\u002For smectite (aluminum oxide), cyclosporine, ciprofloxacin, nitrendipine, or dapsone,\n12. Patients with galactose intolerance, Lapp lactase deficiency, or glucose and galactose malabsorption syndrome (rare hereditary diseases),\n13. Patients participating or in the exclusion period following an interventional research with the use of prohibited medications in this study,\n14. Patients under protective custody.",{"count":274,"type":21},120,[134],"This study is indicated for patients with extended rhegmatogenous retinal detachment (RRD) (≥ 2 quadrants) with macula OFF lasting 7 days or less, pseudophakic or aphakic, and scheduled to undergo surgical intervention with vitrectomy and gas tamponade in one of the ophthalmology departments participating in the study.\n\nThe main objective is to assess the effectiveness of UDCA in visual acuity recovery at 3 months (i.e., the difference between preoperative visual acuity and visual acuity 3 months after surgery) in pseudophakic or aphakic patients who have undergone successful surgical intervention (reattachment of the retina) through vitrectomy and gas tamponade following rhegmatogenous retinal detachment (RRD).\n\n120 patients will be enrolled and randomized in two groups:\n\n* the experimental arm \"UDCA Group,\" with oral administration of ursodeoxycholic acid (Ursolvan®)\n* the control group \"Placebo Group,\" with oral administration of the placebo.",[278],"Retinal Detachment",{"date":280,"type":44},"2025-05-14",{"date":282,"type":44},"2024-08-20",{"date":284,"type":21},"2027-11",{"name":50,"class":51},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":247,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},"100574281","phase-2-dovipa-a-study-evaluating-efficacy-and-safety-of-dostarlimab-and-vitamin-d3-with-mfolfirinox-in-pancreatic-cancer-100574281","NCT06757244","DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","DOVIPA, a Phase II Study Evaluating Efficacy and Safety of DOstarlimab and Oral VItamin D3 With Folinic Acid, 5FU, Irinotecan Plus Oxalipaltin (mFOLFIRINOX) in Non Pretreated Metastatic PAncreatic Cancer","DOVIPA","Inclusion criteria\n\n1. Histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas\n2. No prior treatment for stage IV pancreatic adenocarcinoma (prior adjuvant or neoadjuvant treatment is not allowed)\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1\n4. Male and female patients 18 - 75 years\n5. Measurable disease determined using guidelines of Response Evaluation Criteria In Solid Tumors (RECIST version 1.1)\n6. Accessible tumor tissue available for fresh biopsy\n7. Expected survival \\>3 months\n8. Men and women of child-bearing potential must agree to use adequate contraception.\n\n   A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:\n   * Is not a woman of childbearing potential (WOCBP), or\n   * Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), from the screening visit to at least 6 months after the last dose of study treatment, and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of dostarlimab, and A WOCBP must have a negative highly sensitive pregnancy test (urine or serum, as required by local regulations) within 72 hours before the first dose of study treatment.\n\n   Fertile men who are sexually active with a WOCBP must use a male condom plus spermicide during the trial and for 6 months after the last dose of study treatment administration. Male patients should also refrain from sperm donation throughout this period.\n9. Laboratory values ≤1 week prior to randomization must be Adequate hematologic values\n\n   * Platelet count ≥100,000 cells\u002Fmm3\n   * Absolute neutrophil count \\[ANC\\] ≥1,500 cells\u002Fmm3\n   * Hemoglobin ≥9 g\u002FdL or ≥90 g\u002FL) Adequate hepatic function\n   * Aspartate aminotransferase \\[AST\u002FSGOT\\] ≤2.5x Upper Normal Limit \\[UNL\\] (≤5x UNL if liver metastases present)\n   * Alanine aminotransferase \\[ALT\u002FSGPT\\] ≤ 2.5x Upper Normal Limit (≤5x UNL if liver metastases present)\n   * Bilirubin ≤1.5x UNL\n   * Serum albumin \\> 3.0 g\u002FdL Adequate renal function serum creatinine clearance CLcr ≥ 50 mL\u002Fmin) (Cocroft-Gault Formula should be used for CrCl calculation) For participants not taking warfarin: INR \\\u003C1.5 or PT \\\u003C1.5 x ULN and either PTT or aPTT \\\u003C1.5 x ULN. Participants taking warfarin may be included on a stable dose with a therapeutic INR \\\u003C3.5 Uracilemia \\\u003C 16 ng\u002Fml\n10. Patients with history of hepatitis C (HCV) infection are eligible if HCV viral load is undetectable at screening. HCV screening tests are not required unless there is a known history of HCV infection.\n11. No evidence of active infection and no serious infection within the past 30 days.\n12. Patient able to understand and willing to sign and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures\n13. Patient affiliated to a social security regimen\n\nNon-inclusion criteria\n\n1. Endocrine or acinar pancreatic carcinoma\n2. Participant has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal\u002Fgastric varices, or persistent jaundice.\n\n   Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.\n3. Major surgical procedure, significant traumatic injury within 28 days prior to study treatment start. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study\n4. Known cerebral metastases, central nervous system (CNS), or epidural tumor\n5. Prior anticancer treatment for adenocarcinoma of the pancreas including prior adjuvant or neoadjuvant treatment\n6. Known dose tivity reaction to any of the components of study treatments.\n7. Pregnancy (absence to be confirmed by β-hCG test) or breast-feeding period\n8. Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 months, or high risk of uncontrolled arrhythmia (for men: QTc ≥450 msec, for women: QTc ≥470 msec). Inclusion of patients with hypokalemia, hypomagnesemia and hypocalcemia (defined as results less than normal in Baseline testing) is not allowed.\n9. Previous malignancy in the last 5 years except curative treated basal cell carcinoma of the skin and\u002For in situ carcinoma of the cervix\n10. History or current evidence on physical examination of central nervous system disease or peripheral neuropathy ≥ grade 1 Common Toxicity Criteria for Adverse Events (CTCAE) v5.0.\n11. Any significant disease which, in the investigator's opinion, would exclude the patient from the study.\n12. Patient with a DPD deficiency or UGT1A1 homozygous 7\u002F7; the test should be done for all patients before 5-FU administration, according to ANSM communication regarding recommendation about high risk of no testing DPD in patient before 5-FU administration\n13. Has undergone prior allogeneic hematopoietic stem cell transplantation\n14. Has had an allogeneic tissue\u002Fsolid organ transplant\n15. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)\n16. Participant has received systemic steroid therapy (\\>10 mg daily prednisone or equivalent) within 7 days before the first dose of the study treatment or is receiving any other form of immunosuppressive medication. Replacement therapy (adrenal or pituitary insufficiency) is not considered a form of systemic therapy. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.\n17. Participant has received a live vaccine within 30 days of planned start of study therapy. COVID-19 vaccines that do not contain live viruses are allowed. Note: mRNA and adenoviral-based COVID-19 vaccines are considered non-live.\n18. History of or serology positive for HIV\n19. Patients who have documented presence of HBsAg \\[or HBcAb\\] at Screening or within 3 months prior to first dose of study intervention are excluded. HBV screening tests are not required unless there is a known history of HBV infection.\n20. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n21. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n22. Has an active infection requiring systemic therapy\n23. Allergy: Participant cannot have history of severe allergic and\u002For anaphylactic reactions to chimeric, human or humanized antibodies or fusion proteins, sensitivity to any of the study treatments or components thereof, or a history of drug or other allergy that contraindicates their participation.\n\n    In accordance with the updated SmPC of the products used in this trial, patient cannot be included in the following conditions:\n    * patient has a peripheral sensitive neuropathy with functional impairment prior to first course (contra-indication use with Oxaliplatin)\n    * concomitant use with St John's Wort - Chronic inflammatory bowel disease and\u002For bowel obstruction (contra-indication with Irinotecan)\n    * patient which has been treated with brivudine, sorivudine or their chemically related analogues, which are potent inhibitors of the enzyme dihydropyrimidine dehydrogenase (DPD), which degrades fluorouracil. Fluorouracil must not be taken within 4 weeks of treatment with brivudine, sorivudine or their chemically related analogues (contra-indication with fluorouracil)\n    * patient has diseases\u002Fconditions associated hypercalcaemia and \u002F or hypercalciuria. - Calcium nephrolithiasis, nephrocalcinosis, D- hypervitaminosis\n24. Being deprived of liberty or under guardianship\n25. Potential participants who are pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and\u002For unwilling to use highly effective contraception for up to 6 months after the last dose of study treatment are not eligible for the study.",{"count":295,"type":21},35,[133],"The goal of this clinical trial is to estimate the antitumor response of mFOLFIRINOX + Dostarlimab + oral HD vitamin D3 in patients with non-pretreated histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas. The patients must have an Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) 0 or 1 and adequate organ functions.\n\nThe main objective of the study will be assessed by estimating Objective response rate (ORR) according to Response Evaluation Criteria version 1.1 (RECIST 1.1) in patients with pancreatic adenocarcinoma and measurable disease.\n\nThe Secondary objectives are :\n\n* To assess the safety and tolerability of mFOLFIRINOX + Dostarlimab + HD Vitamin D according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 by evaluating the Median Progression Free Survival (mPFS) in months, the Median Overall Survival (mOS) in months, the Median Duration of Response (mDOR) in months and Clinical benefit rate according to RECIST 1.1 (CBR)\n* To further evaluate the antitumor efficacy of mFOLFIRINOX + Dostarlimab + oral HD Vitamin D by evaluating the type, frequency, and severity of treatment-emergent adverse events (TEAEs); adverse events of special interest (AESIs); safety laboratory findings There are also exploratory objectives to better understand the pancreatic adenocarcinoma.\n\nParticipants will be cared for in the digestive oncology department. A selection review will be carried out to check compliance with the study eligibility criteria. Patients included in the study will be treated with 4 cycles of induction therapy. Each cycle lasts 6weeks and includes chemotherapy such as mFolfirinox D1,D15 and D29, combined with dostarlimab 500 mg every 3 weeks and daily oral vitamin D3.\n\nAt the end of the induction treatment period, maintenance treatment will be instituted with LV5FU chemotherapy combined with dostarlimab 1000 mg every 6 weeks and daily oral vitamine D3. Treatment will be maintained until progression or unacceptable toxicity.\n\nThroughout this period, patients will be monitored for their safety. Imaging examinations will also be carried out to monitor the progression of tumour disease.",[299],"Pancreas Neoplasms",[301,302,303,304,305,306],"Pancreatic adenocarcinoma","metastatic PAncreatic Cancer","dostarlimab","vitamin D3","mFolfirinox","LV5FU","2025-03-14",{"date":309,"type":44},"2025-03-18",{"date":311,"type":44},"2025-02-18",{"date":313,"type":21},"2028-02-18",{"name":50,"class":51},5,{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":322,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":52},"100338697","feasibility-study-of-uterine-transplantation-from-living-donors-in-terms-of-efficacy-and-safety-in-patients-with-mayer-rokitansky-kster-hauser-syndrome-mrkh-100338697","NCT03689842","Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH)","Inclusion Criteria:\n\nGraft recipient is a patient with Mayer-Rokitansky-Küster-Hauser Type I Uterine Vaginal Agenesis (without renal, cardiac and bone malformations):\n\n* Being aged between 18 and 38 years old\n* In stable couple, with a pregnancy project, favorable psychological evaluation\n* No history of cancer and transfusion\n\nThe living donor is a woman related to the Graft recipient with\n\n* Absence of comorbidity (neurological, nephro-urological pathology, infectious, psychiatric or psychological pathology)\n* Absence of uterine surgery, abdomino-pelvic major pathology history\n\nExclusion Criteria:\n\nGraft recipient:\n\n* Extreme oligo-astheno-spermia and azoospermia in the husband\n* History of abdominopelvic surgery excluding uncomplicated appendectomy; vaginal residue not allowing anastomosis\n\nLiving donor :\n\n* Known thromboembolic risk factor\n* No Compatibility with the recipient (group, rhesus, HLA)",true,{"count":324,"type":21},20,[24],"In France, one in 4500 women is affected by the MayerRokitantskyKüsterHauser (MRKH) syndrome which is characterized by the absence of uterus at birth. Currently, the only solutions for these patients are:\n\n* Gestational surrogacy, prohibited in France\n* Adoption\n* Resignation\n\nUterine transplantation could become a good alternative.\n\nThis study is conducted in 10 patients with MRKH type I syndrome, who will be transplanted from a living donor uterus",[328],"Mayer Rokitansky Kuster Hauser Syndrome","2025-03-04",{"date":331,"type":44},"2025-03-07",{"date":333,"type":44},"2017-12-14",{"date":335,"type":21},"2034-12-14",{"name":50,"class":51},{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":322,"sex":61,"minAge":345,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":348,"phases":4,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":4},"100564639","evaluation-of-the-impact-of-a-hpv-vaccination-talk-with-third-grade-students-100564639","NCT06631794","Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students","Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students on Their Papillomavirus Vaccination Coverage.","HPV-ADO","Inclusion Criteria:\n\n* 3rd grade students enrolled in public secondary schools in Suresnes and Rueil-Malmaison.\n\nExclusion Criteria:\n\n* Students absent on the day of the talk.\n* Students unwilling\u002Funable to complete questionnaire.","14 Years",{"count":347,"type":21},1170,"OBSERVATIONAL","This is a prospective pragmatic study to assess the impact of a HPV vaccination talk in secondary school on actual vaccine dispensing in test communes compared with control communes. The talk consist on a briefing on the importance of vaccination.\n\nThis is a controlled study, since two communes will benefit from the HPV vaccination talk, while the other two will serve as controls without set up of the HPV vaccination talk. The set up of this presentation will be open-label.",[351],"Teenagers","2024-10-07",{"date":354,"type":44},"2024-10-08",{"date":356,"type":21},"2024-10-23",{"date":358,"type":21},"2025-10-01",{"name":50,"class":51},{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":385},"100463866","contact-aspiration-versus-stent-retriever-for-recanalisation-of-acute-stroke-patients-with-basilar-artery-occlusion-the-posterior-circulation-aster-randomized-trial-protocol-100463866","NCT05320263","Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol","Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial","pc-ASTER","Inclusion Criteria:\n\nAge ≥ 18 years\n\n* AIS with BAO on non-invasive imaging (CT or MRI)\n* Eligible for thrombectomy : groin puncture undergone within 24 hours of first symptoms or of last time the patient was seen normal\n* Being covered by a national health insurance\n* Informed consent obtained from the patients\u002Fhis proxy or following an emergency procedure\n\nExclusion Criteria:\n\n* Known or suspected pre-existing (chronic) large vessel stenosis \u002F occlusion in the symptomatic territory (basilar artery)\n* Severe contrast medium allergy or absolute contraindication to use of iodinated products\n* Clinical history, past imaging or clinical judgment suggesting intracranial stenosis of the basilar artery\n* Pregnancy (urine or serum beta HCG test for women of child-bearing potential)\n* Person deprived of liberty\n* Patient benefiting from a legal protection (guardianship or curatorship)",{"count":369,"type":21},480,[24],"Acute ischemic stroke (AIS) patients with basilar artery occlusion (BAO) present a devastating, life-threatening prognosis.\n\nUrgent recanalization with endovascular mechanical thrombectomy is routinely performed in patients with BAO although the level of evidence is lower than that in anterior circulation occlusions (randomization in this population versus medical treatment alone having been impossible in recent studies). Recently, a large retrospective study supports the interest of thrombectomy in this population .\n\nSpeed and grade of the recanalisation have a major impact on clinical outcome. Favorable outcome at 90 days is strongly associated with the successful recanalization status at the end of the endovascular procedure (OR=4.57, 95%CI=1.24-16.87, P=0.023).\n\nFirst pass effect has been shown to be a strong marker of efficacy of endovascular procedure with significant correlation with clinical outcome.\n\nThrombectomy with Stent retrievers dramatically changed the prognosis of anterior circulation large vessel occlusion strokes and currently used in BAO patients (posterior circulation). Contact aspiration (CA) is currently used in anterior large vessel occlusions (COMPASS trial, Lancet 2019), with similar rates of recanalization and favorable outcomes (Boulanger M, 2019), as well as in BAO patients .\n\nHowever, the benefit of CA compared to SR for the treatment of BAO remains under debate with the superiority of first line CA compared to SR or no difference. Available data are based on retrospective studies with no data from RCT.\n\nIn this context, a randomized controlled trial is needed to assess the benefit of CA versus SR.",[373],"Basilar Artery Occlusion",[375,376],"Stroke","Basilar artery occlusion","2023-02-27",{"date":379,"type":44},"2023-03-01",{"date":381,"type":44},"2022-11-19",{"date":383,"type":21},"2027-07",{"name":50,"class":51},12,{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":61,"minAge":203,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":22,"phases":395,"briefSummary":396,"conditions":397,"keywords":402,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":52},"100426771","diagnostic-and-prognostic-biomarkers-of-transplant-dysfunction-in-the-context-of-lung-transplantation-100426771","NCT04837339","Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation","DATACOL","Inclusion Criteria:\n\n* Men or women over 15 years of age\n* Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant\n* Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has\u002Fhave signed the informed consent.\n* Be affiliated with a Health Insurance plan.\n\nExclusion Criteria:\n\n* Pregnant, parturient and\u002For lactating woman\n* Hemoglobin level less than or equal to 8g\u002Fdl\n* Persons of full age who are subject to a legal protection measure or who are unable to express their consent\n* Persons under the protection of justice\n* Not being able to follow the study requirements for geographical, social or psychological reasons\n* Patient refusal.",{"count":394,"type":21},900,[24],"Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation.\n\nEach dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.",[398,399,400,401],"Lung Transplant Rejection","Lung Transplant Failure","Lung Transplant; Complications","Lung Transplant Failure and Rejection",[391],"2022-08-02",{"date":405,"type":44},"2022-08-03",{"date":407,"type":44},"2022-03-17",{"date":409,"type":21},"2037-03",{"name":50,"class":51},""]